Logos Global reports 4.6% stake in iBio shares
iBio, Inc. received an amended Schedule 13G filing showing that Logos Global Management LP and affiliated entities report beneficial ownership of 1,500,000 shares of iBio common stock.
Rhea-AI Filing Summary
iBio, Inc. received an amended Schedule 13G filing showing that Logos Global Management LP and affiliated entities report beneficial ownership of 1,500,000 shares of iBio common stock. This stake represents 4.6% of the outstanding common shares, based on 32,540,942 shares outstanding as of January 30, 2026, as cited from iBio’s Form S-3.
The filing attributes the same 1,500,000-share, 4.6% position to Logos Global Management LP, Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Arsani William, with shared voting and dispositive power over all reported shares and no sole power. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of iBio. They also jointly file while expressly disclaiming group status and beneficial ownership beyond their pecuniary interest.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in iBio (IBIO) does Logos Global report in this Schedule 13G/A?
Who are the reporting persons in the iBio (IBIO) Schedule 13G/A amendment?
Does the iBio (IBIO) Schedule 13G/A indicate an attempt to influence control of the company?
What is the date of the event triggering this iBio (IBIO) Schedule 13G/A filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.